Important new therapies for methicillin-resistant Staphylococcus aureus
The DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
Introduction: Methicillin-resistant Staphylococcus aureus (MRSA) infections represent a leading cause of infection-related morbidity and mortality worldwide. There has been a welcome increase in the number of agents available for the treatment of MRSA infection over the last decade and several clinical trials are currently investigating the role of new experimental strategies.Areas covered: The purpose of this manuscript is to review the efficacy and safety of recently approved anti-MRSA molecules as well as some newer agents currently under investigation with a specific focus on the potential role of these drugs in everyday clinical practice.Expert opinion: Many new drugs with an activity against MRSA have been recently approved or are in an advanced stage of development. All these compounds represent promising options to enhance our antibiotic armamentarium. However, data regarding the use of these new compounds in real-life terms are limited and their best placement in therapy and in terms of optimization of medical resources and balance of cost-effectiveness requires further investigation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“By comparison, six distinct classes of antibiotics are currently available to treat methicillin-resistant Staphylococcus aureus (MRSA), an important and widespread drug-resistant bacterium6.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [6]
Citations
The citation lists are queued
They are fetched later and appear here then.
References 170 · Cited by 21
Research works printed but not linked: 1
- Dunne Michael RU Puttagunta sailaja intrapulmonary and plasma concentrations of dalbavancin in healthy adults after a single 1500 mg infusion. Presented at the 26th European Congress of Clinical microbiology and Infectious Diseases (ECCMID). Amsterdam Netherlands; 2016. · doi:10.26226/morressier.56d6be79d462b80296c97b37
Metadata
- Authors
- Bassetti, M., Carnelutti, A., Castaldo, N., & Peghin, M.
- Affiliations
- Ospedale Policlinico San Martino (IT)
- University of Udine (IT)
- Corresponding author
- Bassetti, Matteo
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa UK Limited
- Published
- 2019-10-17
- Volume
- 20
- Issue
- 18
- Pages
- 2317-2334
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2980531877
- Cited by
- 21
- References
- 170
- Citations by year
- 2025: 4 · 2024: 1 · 2023: 3 · 2022: 1 · 2021: 5 · 2020: 7
- FWCI
- 0.45
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Pharmacotherapy (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System (University of Udine) (submittedVersion)
- IrInSubria (University of Insubria) (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- methicillin-resistant Staphylococcus aureus, MRSA infection, anti-MRSA agents, drug safety and efficacy, cost-effectiveness
- MeSH terms
- Anti-Bacterial Agents, Humans, Staphylococcal Infections, Methicillin-Resistant Staphylococcus aureus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Important new therapies for methicillin-resistant Staphylococcus aureus. https://app.cochat.ai/papers/10.1080/14656566.2019.1675637
- The paper
- Bassetti, M., Carnelutti, A., Castaldo, N., & Peghin, M. (2019). Important new therapies for methicillin-resistant Staphylococcus aureus. Expert Opinion on Pharmacotherapy. https://doi.org/10.1080/14656566.2019.1675637
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.